AstraZeneca Stock News

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus's investigational HIF-2a inhibitor, in combi...

PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides. As part o...

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.

AstraZeneca PLC (NASDAQ:AZN ) Deutsche Bank's Depositary Receipts Virtual Investor Conference September 24, 2024 11:30 AM ET Company Participants Elizabeth Walton - Director, Investor Relations Conference Call Participants Zafar Aziz - Deutsche Bank Hello and welcome to the Deutsche Bank Depositary Receipts of Virtual Investor Conference. My name is Zafar Aziz from the Deutsche Bank team.

AstraZeneca possesses all the key qualities of a qualitative dividend stock. The company topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. AstraZeneca boasts a balance sheet that's A-rated by S&P.

British drugmaker AstraZeneca (AZN) said Monday that a Phase 3 trial of a developmental drug failed to achieve "statistical significance" in improving the length of time patients with certain types of breast cancer lived.

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.

AstraZeneca PLC (LSE:AZN) shares fell to a five-month low after it confirmed that another failed cancer trial of its Dato-DXd drug. The largest company in the FTSE 100 said it will continue to talk to regulators despite Phase III trial results of datopotamab deruxtecan (Dato-DXd) on patients with late-stage breast cancer showed it “did not achieve statistical significance”, ie help survival rat...